Lepzacitinib

Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib exhibits anti-inflammatory effect and inhibits atopic dermatitis and other skin diseases[1].

Product Specifications

CAS Number

[2321488-47-3]

UNSPSC

12352005

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lepzacitinib.html

Purity

99.30

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCOC(C1=CN=C(NC=C2)C2=C1N[C@H]3CN(CCC3)C(CC#N)=O)=O

Molecular Formula

C18H21N5O3

Molecular Weight

355.39

References & Citations

[1]Anderson, et al. Preparation of substituted pyrrolopyridine compounds as JAK inhibitors. World Intellectual Property Organization, WO2019090158 A1 2019-05-09.